Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Decade in review—IBD

IBD—genes, bacteria and new therapeutic strategies

Nature Reviews Gastroenterology & Hepatology volume 11, pages 652–654 (2014)Cite this article

Subjects

IBD is known to be associated with an abnormal response to an unbalanced gut microbiota in genetically predisposed individuals. The therapeutic goal now is to control progression of the disease. Given the heterogeneity of IBD, the two universes of basic and clinical science must work in parallel to realize the hope of personalized therapy.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: A treat-to-target strategy could be applied to all patients with IBD.

References

  1. Jostins, L. et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119–124 (2012).

    Article  CAS  Google Scholar 

  2. Glocker, E. O. et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med. 361, 2033–2045 (2009).

    Article  CAS  Google Scholar 

  3. Cadwell, K. et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 456, 259–263 (2008).

    Article  CAS  Google Scholar 

  4. Adolph, T. E. et al. Paneth cells as a site of origin for intestinal inflammation. Nature 503, 272–276 (2013).

    Article  CAS  Google Scholar 

  5. Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S. & Medzhitov, R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118, 229–241 (2004).

    Article  CAS  Google Scholar 

  6. Buonocore, S. et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 464, 1371–1375 (2010).

    Article  CAS  Google Scholar 

  7. Gevers, D. et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 15, 382–392 (2014).

    Article  CAS  Google Scholar 

  8. Colombel, J. F. et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 362, 1383–1395 (2010).

    Article  CAS  Google Scholar 

  9. Feagan, B. G. et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369, 699–710 (2013).

    Article  CAS  Google Scholar 

  10. Lee, J. C. et al. Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J. Clin. Invest. 121, 4170–4179 (2011).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Icahn School of Medicine at Mount Sinai, 1428 Madison Avenue, New York, 10029, NY, USA

    Jean-Frederic Colombel

Authors
  1. Jean-Frederic Colombel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-Frederic Colombel.

Ethics declarations

Competing interests

J.-F.C. has served as consultant, advisory board member or speaker for Abbvie, ABScience, Amgen, Bristol Meyers Squibb, Celltrion, Danone, Ferring, Genentech, Giuliani SPA, Given Imaging, Janssen, Immune Pharmaceuticals, Merck, Millenium Pharmaceuticals, Nutrition Science Partners, Pfizer. Prometheus Laboratories, Protagonist Therapeutics, Receptos, Sanofi, Schering Plough, Second Genome, Takeda, Teva Pharmaceuticals, UCB Pharma, Vertex and Dr August Wolff.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Colombel, JF. IBD—genes, bacteria and new therapeutic strategies. Nat Rev Gastroenterol Hepatol 11, 652–654 (2014). https://doi.org/10.1038/nrgastro.2014.170

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2014.170

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research